Coherus Oncology (CHRS) Total Debt Growth (5y) (2019 - 2026)
Coherus Oncology (CHRS) Total Debt Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.04% |
| Dec 31, 2025 | -13.03% |
| Sep 30, 2025 | 6.87% |
| Jun 30, 2025 | -13.02% |
| Mar 31, 2025 | -13.01% |
| Dec 31, 2024 | -13.01% |
| Sep 30, 2024 | -13.00% |
| Jun 30, 2024 | 7.07% |
| Mar 31, 2024 | 22.87% |
| Sep 30, 2023 | 57.68% |
| Jun 30, 2023 | 57.25% |
| Mar 31, 2023 | 57.33% |
| Dec 31, 2022 | 53.62% |
| Sep 30, 2022 | 54.26% |
| Jun 30, 2022 | 49.18% |
| Mar 31, 2022 | 48.66% |
| Dec 31, 2021 | 21.43% |
| Sep 30, 2021 | 20.21% |
| Jun 30, 2021 | 18.95% |
| Mar 31, 2021 | 23.25% |